pilot studies conducted in three African nations. In 2019, malaria claimed 274,000 African children under the age of five, and over half of the global population is at risk of infection.
Since 2019, the WHO has organized several large-scale trial studies in African continents in which 2.3 million doses of Mosquirix have been given to newborns in Ghana, Kenya, and Malawi. The deadly disease mostly kills children under the age of five. This initiative was the outcome of a decade-long clinical studies in seven African nations.
Tedros Adhanom Ghebreyesus, WHO director-general, expressed pride. He said, “This is a vaccine developed in Africa by African scientists and we’re very proud”. He continued, pointing to anti-malaria initiatives such as mosquito nets for beds and mosquito sprays to eliminate disease-transmitting insects. He added, “Using this vaccine in addition to existing tools to prevent malaria could save tens of thousands of young lives each year”.
One of the components in the Mosquirix vaccine is derived from…
